Shen Qun, Zhou Jian-Wei, Zhu Guang-Rong, Yang Yue-Yan, Qiu Hai-Rong, Zhu Guang-Rong, Xia Wen, Jiang Peng-Jun
Department of Molecular Toxicology, College of Public Health, Nanjing Medical University, Nanjing 210029, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):247-51.
This study was aimed to investigate the clinical, pathological and biological features of a special case of chronic myeloid leukemia (CML) with marked thrombocythemic onset. The morphological changes of cells were analyzed by using bone marrow smear and biopsy; Ph chromosome, a specific marker of CML, was assayed by conventional chromosomal analysis and fluorescence in situ hybridization, bcr/abl fusion gene was detected by reverse transcription-polymerase chain reaction. The results indicated that CML mimicked essential thrombocythemia (ET) at presentation was relatively rare and might be misdiagnosed as ET, bone marrow smear and biopsy revealed, marked thrombocytosis and moderate leukocytosis; RT-PCR, FISH and conventional chromosomal analysis demonstrated the existence of Ph chromosome and bcr/abl fusion gene. This special CML could progress into accelerated phase or blast crisis. The megakaryocytes in Ph+ ET were smaller than normal ones and had typically hypolobulated round nuclei. Patients diagnosed as Ph+ ET might progress into CML and showed a high tendency to myelofibrosis and blastic transformation. It is concluded that the value of routine cytogenetical and molecular biological analysis in diagnosis for potential CML cases, which mimicked ET as in this presentation, is very distinctive, and the importance is magnified by the recent availability of imatinib, a specific inhibitor of the bcr/abl tyrosine kinase produced by the Philadelphia chromosome. Every case of "ET" should be tested for the Philadelphia chromosome and bcr/abl transcript.
本研究旨在探讨以显著血小板增多起病的慢性髓系白血病(CML)特殊病例的临床、病理及生物学特征。通过骨髓涂片和活检分析细胞的形态学变化;采用常规染色体分析和荧光原位杂交检测CML的特异性标志物Ph染色体,通过逆转录-聚合酶链反应检测bcr/abl融合基因。结果表明,初诊时酷似原发性血小板增多症(ET)的CML相对少见,可能被误诊为ET,骨髓涂片和活检显示血小板显著增多和中度白细胞增多;逆转录-聚合酶链反应、荧光原位杂交和常规染色体分析证实存在Ph染色体和bcr/abl融合基因。这种特殊的CML可进展为加速期或急变期。Ph+ET中的巨核细胞比正常巨核细胞小,核呈典型的分叶减少的圆形。诊断为Ph+ET的患者可能进展为CML,并显示出骨髓纤维化和原始细胞转化的高倾向。结论是,对于初诊时酷似ET的潜在CML病例,常规细胞遗传学和分子生物学分析在诊断中的价值非常显著,而最近可用的伊马替尼(一种由费城染色体产生的bcr/abl酪氨酸激酶的特异性抑制剂)更凸显了其重要性。每例“ET”病例均应检测费城染色体和bcr/abl转录本。